Pharma courses

Pharma Admission

pharma courses

pharma admission

Mechanisms of Atorvastatin - induced impairment of mitochondrial permeability and Co enzyme Q level.
Statins are potent lipid-lowering drugs which reduce the concentrations of low density lipoprotein (LDL) cholesterol. Statins are competitive inhibitors of 3-hydroxy-3- methylglutarylcoenzyme A (HMG-CoA) reductase - a rate limiting enzyme in cholesterol biosynthesis - which converts HMG-CoA to mevalonate.43Mevalonate is a precursor of cholesterol but also of a whole class of other important substances, such as ubiquinone, dolichols and other isoprenoids44. Statins are not free from side effects despite being considered as safe drugs.45Although infrequent, hepatotoxicity  and myopathy are two of the most common complications associated with this class of drugs, especially when used at maximum doses, or when combined with other lipid lowering drugs such as fibrates, or combined with drugs that use the same enzymatic pathway as cytochrome P450 (CYP450) in its metabolic pathway, or in the elderly, or in subjects having considerable hepatic and/or renal dysfunction.45

Many studies have demonstrated that statins decrease CoQ concentration in plasma and various tissues of experimental animals. Atorvastatin administered for only 14 days decreased plasma CoQ by about 50% in patients with hypercholesterolemia43. Ubiquinone depletion induced by statin therapy may be accompanied by impaired mitochondrial function, as evidenced by reduced oxygen consumption and reduced capacity of the respiratory chain and rate of ATP synthesis in the liver mitochondria.

Thus, both CoQ levels (and thus antioxidant defence) and membrane lipid composition, which might depress oxygen consumption and energy production in the mitochondria.46

In physiological conditions mitochondrial function are an index of uptake of oxygen, calcium handling, production of ATP, and regulation of respiratory chain function. Mitochondrial lipid peroxidation alters membrane integrity and permeability of mitochondria. Thus alteration of Atorvastatin result in modulation of mitochondrial function leads to irreversible liver injury.44

Mitochondrial functions are an index of uptake of oxygen, calcium handling, and production of ATP and regulation of respiratory chain function in physiological conditions. Mitochondrial lipid peroxidation alters membrane integrity and permeability of mitochondria. Thus modulation of mitochondrial function owing to Atorvastatin leads to irreversible liver injury.

1.Rao AS, Ahmed MF, Ibrahim M. Hepatoprotective activity of Melia azedarach leaf extract against simvastatin induced Hepatotoxicity in rats. Journal of Applied Pharmaceutical Science,2012 2(07): 144-8.
2.Begriche K, Massart J, Robin MA, Borgne-Sanchez A, Fromenty B. Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J Hepatol,2011 54(4): 773-94.
3.MITCHELL P. Compartmentation and communication in living systems. Ligand conduction: a general catalytic principle in chemical, osmotic and chemiosmotic reaction systems. Eur J Biochem,1979 95(1): 1-20.
4.Bernardi P, Krauskopf A, Basso E, Petronilli V, Blalchy?Dyson E, Di Lisa F, et al. The mitochondrial permeability transition from in vitro artifact to disease target. FEBS Journal,2006 273(10): 2077-99.
5.Labbe G, Pessayre D, Fromenty B. Drug?induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam Clin Pharmacol,2008 22(4): 335-53.
6.Pessayre D, Mansouri A, Berson A, Fromenty B. Mitochondrial involvement in drug-induced liver injury. Adverse Drug Reactions: Springer; 2010. p. 311-65.
7.Malhi H, Gores GJ, Lemasters JJ. Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology,2006 43(S1): S31-S44.
8.Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nature reviews Drug discovery,2010 9(6): 447-64.
9.Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med,2000 6(5): 513-9.
10.Buron N, Porceddu M, Brabant M, Desgué D, Racoeur C, Lassalle M, et al. Use of human cancer cell lines mitochondria to explore the mechanisms of BH3 peptides and ABT-737-induced mitochondrial membrane permeabilization. PLoS One,2010 5(3): e9924.
11.Balakirev MY, Zimmer G. Mitochondrial injury by disulfiram: two different mechanisms of the mitochondrial permeability transition. Chem Biol Interact,2001 138(3): 299-311.
12.Belosludtsev KN, Saris N-EL, Belosludtseva NV, Trudovishnikov AS, Lukyanova LD, Mironova GD. Physiological aspects of the mitochondrial cyclosporin A-insensitive palmitate/Ca2+-induced pore: tissue specificity, age profile and dependence on the animal’s adaptation to hypoxia. J Bioenerg Biomembr,2009 41(4): 395-401.
13.Eliseev RA, Filippov G, Velos J, VanWinkle B, Goldman A, Rosier RN, et al. Role of cyclophilin D in the resistance of brain mitochondria to the permeability transition. Neurobiol Aging,2007 28(10): 1532-42.
14.Mirandola SR, Melo DR, Saito Â, Castilho RF. 3?nitropropionic acid?induced mitochondrial permeability transition: Comparative study of mitochondria from different tissues and brain regions. J Neurosci Res,2010 88(3): 630-9.
15.Wallace DC, Fan W, Procaccio V. Mitochondrial energetics and therapeutics. Annual review of pathology,2010 5 297.
16.Seifert EL, Estey C, Xuan JY, Harper M-E. Electron transport chain-dependent and-independent mechanisms of mitochondrial H2O2 emission during long-chain fatty acid oxidation. J Biol Chem,2010 285(8): 5748-58.
17.Marí M, Morales A, Colell A, García-Ruiz C, Fernández-Checa JC. Mitochondrial glutathione, a key survival antioxidant. Antioxidants & redox signaling,2009 11(11): 2685-700.
18.Fernandez-Checa JC, Kaplowitz N. Hepatic mitochondrial glutathione: transport and role in disease and toxicity. Toxicol Appl Pharmacol,2005 204(3): 263-73.
19.Jones DP, Lemasters JJ, Han D, Boelsterli UA, Kaplowitz N. Mechanisms of pathogenesis in drug hepatotoxicity putting the stress on mitochondria. Molecular interventions,2010 10(2): 98.
20.Brookes PS. Mitochondrial H< sup>+</sup> leak and ROS generation: An odd couple. Free Radic Biol Med,2005 38(1): 12-23.
21.Tahara EB, Navarete FD, Kowaltowski AJ. Tissue-, substrate-, and site-specific characteristics of mitochondrial reactive oxygen species generation. Free Radic Biol Med,2009 46(9): 1283-97.
22.Demeilliers C, Maisonneuve C, Grodet A, Mansouri A, Nguyen R, Tinel M, et al. Impaired adaptive resynthesis and prolonged depletion of hepatic mitochondrial DNA after repeated alcohol binges in mice. Gastroenterology,2002 123(4): 1278-90.
23.Sanz A, Caro P, Ayala V, Portero-Otin M, Pamplona R, Barja G. Methionine restriction decreases mitochondrial oxygen radical generation and leak as well as oxidative damage to mitochondrial DNA and proteins. The FASEB journal,2006 20(8): 1064-73.
24.Velsor LW, Kovacevic M, Goldstein M, Leitner HM, Lewis W, Day BJ. Mitochondrial oxidative stress in human hepatoma cells exposed to stavudine. Toxicol Appl Pharmacol,2004 199(1): 10-9.
25.Fromenty B, Robin M, Igoudjil A, Mansouri A, Pessayre D. The ins and outs of mitochondrial dysfunction in NASH. Diabetes Metab,2004 30(2): 121-38.
26.Fromenty B, Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther,1995 67(1): 101-54.
27.Arnaudo E, Shanske S, DiMauro S, Schon E, Moraes C, Dalakas M. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. The Lancet,1991 337(8740): 508-10.
28.Lai KK, Gang DL, Zawacki JK, Cooley TP. Fulminant hepatic failure associated with 2′, 3′-dideoxyinosine (ddI). Ann Intern Med,1991 115(4): 283-4.
29.Le Bras P, D'Oiron R, Quertainmont Y, Halfon P, Caquet R. Metabolic, hepatic and muscular changes during zidovudine therapy: a drug-induced mitochondrial disease? AIDS,1994 8(5): 715-6.
30.Nadanaciva S, Will Y. The role of mitochondrial dysfunction and drug safety. IDrugs: the investigational drugs journal,2009 12(11): 706-10.
31.Berson A, Cazanave S, Descatoire V, Tinel M, Grodet A, Wolf C, et al. The anti-inflammatory drug, nimesulide (4-nitro-2-phenoxymethane-sulfoanilide), uncouples mitochondria and induces mitochondrial permeability transition in human hepatoma cells: protection by albumin. J Pharmacol Exp Ther,2006 318(1): 444-54.
32.Kaufmann P, Török M, Hänni A, Roberts P, Gasser R, Krähenbühl S. Mechanisms of benzarone and benzbromarone?induced hepatic toxicity. Hepatology,2005 41(4): 925-35.
33.Trost LC, Lemasters JJ. The mitochondrial permeability transition: a new pathophysiological mechanism for Reye's syndrome and toxic liver injury. J Pharmacol Exp Ther,1996 278(3): 1000-5.
34.Berson A, Descatoire V, Sutton A, Fau D, Maulny B, Vadrot N, et al. Toxicity of alpidem, a peripheral benzodiazepine receptor ligand, but not zolpidem, in rat hepatocytes: role of mitochondrial permeability transition and metabolic activation. J Pharmacol Exp Ther,2001 299(2): 793-800.
35.Masubuchi Y, Kano S, Horie T. Mitochondrial permeability transition as a potential determinant of hepatotoxicity of antidiabetic thiazolidinediones. Toxicology,2006 222(3): 233-9.
36.Masubuchi Y, Suda C, Horie T. Involvement of mitochondrial permeability transition in acetaminophen-induced liver injury in mice. J Hepatol,2005 42(1): 110-6.
37.Kowaltowski AJ, Castilho RF, Vercesi AE. Mitochondrial permeability transition and oxidative stress. FEBS Lett,2001 495(1): 12-5.
38.Hinson JA, Roberts DW, James LP. Mechanisms of acetaminophen-induced liver necrosis. Adverse Drug Reactions: Springer; 2010. p. 369-405.
39.Burcham PC, Harman AW. Acetaminophen toxicity results in site-specific mitochondrial damage in isolated mouse hepatocytes. J Biol Chem,1991 266(8): 5049-54.
40.Ruepp SU, Tonge RP, Shaw J, Wallis N, Pognan F. Genomics and proteomics analysis of acetaminophen toxicity in mouse liver. Toxicol Sci,2002 65(1): 135-50.
41.Kaplowitz N, Shinohara M, Liu Z-X, Han D. How to protect against acetaminophen: don't ask for JUNK. Gastroenterology,2008 135(4): 1047-51.
42.Sohn JH, Han KL, Kim J-H, Rukayadi Y, Hwang J-K. Protective effects of macelignan on cisplatin-induced hepatotoxicity is associated with JNK activation. Biol Pharm Bull,2008 31(2): 273-7.
43.Be?towski J, Wójcicka G, Jamroz-Wi?niewska A. Adverse effects of statins-mechanisms and consequences. Curr Drug Saf,2009 4(3): 209-28.
44.ULI?NÁ O, VAN?OVÁ O, WACZULÍKOVÁ I, BOŽEK P, ŠIKUROVÁ L, BADA V, et al. Liver mitochondrial respiratory function and coenzyme Q content in rats on a hypercholesterolemic diet treated with atorvastatin. Physiological research/Academia Scientiarum Bohemoslovaca,2012 61(2): 185.
45.Cueto R, Valdivielso P, Lucena MI, García-Arias C, Andrade RJ, González-Santos P. Statins: Hepatic Disease and Hepatotoxicity Risk. Open Gastroenterology Journal,2008 2 18-23.
46.Langsjoen PH, Langsjoen AM. The clinical use of HMG CoA?reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human publications. Biofactors,2003 18(1?4): 101-11.


SUBMIT YOUR ARTICLE/PROJECT AT articles@pharmatutor.org

Subscribe to Pharmatutor Alerts by Email